CTLA4 and neoplasm: For instance, sorafenib and IFN-α combined with herbal compound inhibited the EMT of HCC cells after iRFA (28, 29); bevacizumab inhibited the tumor growth and angiogenesis induced by iRFA (30); and CTLA-4 blockade suppressed the growth of residual tumors and improved survival in a subcutaneous murine HCC model (31).